An attempt to improve low chemotherapy sensitivity of ovarian clear cell carcinoma

• Project/Area Number: 25871147
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Human pathology; Obstetrics and gynecology
• Research Institution: Sasaki Foundation
• Principal Investigator: KIKUCHI Ryoko 公益財団法人佐々木研究所, 附属研究所, 研究員(移行) (80535063)
• Project Period (FY): 2013-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000); Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 卵巣明細胞腺癌 / パクリタキセル / 分子標的治療 / 蛍光標識二次元ディファレンスゲル電気泳動法 / CTGF / Mascot解析 / 2D-DIGE / 頭頸部扁平上皮癌

Outline of Final Research Achievements

We used 4 ovarian clear cell carcinoma cell lines to identify 2 paclitaxel sensitive cell lines and 2 paclitaxel resistant cell lines. We used 2 Dimensional Fluorescence Difference Gel Electrophoresis (2D-DIGE) to identify 4 proteins that have high protein expressions in 2 paclitaxel resistant cell lines in common and low protein expressions in 2 paclitaxel sensitive cell lines in common. One of the 4 proteins was protein 1 (labo name). Protein 1 was reported to induce drug resistance in other carcinoma, but was not reported to induce drug resistance in ovarian clear cell carcinoma. Protein 1 might be a new candidate of paclitaxel sensitive marker and protein 1-targeted therapy might enhance paclitaxel sensitivity of ovarian clear cell carcinoma.

Research Products

• [Journal Article] カボザンチニブの併用は再発子宮平滑筋肉腫へのテモゾロミドとペパシズマブの治療効果を高める． (2015)
  • Author(s): 池田さやか, 工藤一弥, 佐々木直樹, 後藤友子, 高野政志, 菊池良子, 坂本優, 喜多恒和, 菊池義公.
  • Journal Title: 日本婦人科腫瘍学会雑誌 Volume: 33 Pages: 564-564
• [Journal Article] The expression and clinical significance of connective tissue growth factor in advanced head and neck squamous cell cancer. (2014)
  • Author(s): Kikuchi R, Kikuchi Y, Tsuda H, Maekawa H, Kozaki KI, Imoto I, Tamai S, Shiotani A, Iwaya K, Sakamoto M, Sekiya T, Matsubara O
  • Journal Title: Human Cell Volume: 印刷中 Issue: 3 Pages: 121-128
  • DOI: 10.1007/s13577-014-0092-0
  • Peer Reviewed
• [Presentation] Weekly administration of bevacizumab, eribulin and oxalilplatin in patients with platinum-resistant ovarian carcinomas: a phase II study with biomarker analysis. (2015)
  • Author(s): Kazuya Kudoh, Yuji Ikeda, Masashi Takano, Hiroko Kouta, Tsunekazu Kita, Ryoko Kikuchi, Morikazu Miyamoto, Tomoyuki Yoshikawa, Tomoko Goto, Kenichi Furuya, Yutaka Tamada, Arata Suga, Yoshihiro Kikuchi
  • Organizer: The 51th Annual Meeting of the American Society of Clinical Oncology (ASCO)
  • Place of Presentation: Chicago, USA
  • Year and Date: 2015-05-29
  • Int'l Joint Research
• [Presentation] Combination therapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: A phase II study with biomarker analysis. (2015)
  • Author(s): Masashi Takano, Hiroko Kouta, Kazuya Kudoh, Tsunekazu Kita, Ryoko Kikuchi, Morikazu Miyamoto, Tomoyuki Yoshikawa, Tomoko Goto, Kenichi Furuya, Yutaka Tamada, Arata Suga, Yoshihiro Kikuchi
  • Organizer: The 51th Annual Meeting of the American Society of Clinical Oncology (ASCO)
  • Place of Presentation: Chicago, USA
  • Year and Date: 2015-05-29
  • Int'l Joint Research
• [Presentation] Synergistic effects of cabozantinib to temozolomide and bevacizumab in patients with heavily pretreated relapsed uterine leiomyosarcoma. (2015)
  • Author(s): Sayaka Ikeda, Kazuya Kudoh, Naoki Sasaki, Masashi Takano, Tomoko Goto, Ryoko Kikuchi, Masaru Sakamoto, Tsunekazu Kita, Nobuyuki Susumu, Daisuke Aoki, Hiroko Kouta, Yoshihiro Kikuchi
  • Organizer: The 51th Annual Meeting of the American Society of Clinical Oncology (ASCO)
  • Place of Presentation: Chicago, USA
  • Year and Date: 2015-05-29
  • Int'l Joint Research